camostat has been researched along with Critical Illness in 1 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
Critical Illness: A disease or state in which death is possible or imminent.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sakr, Y | 1 |
| Bensasi, H | 1 |
| Taha, A | 1 |
| Bauer, M | 1 |
| Ismail, K | 1 |
1 other study available for camostat and Critical Illness
| Article | Year |
|---|---|
Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia.
Topics: COVID-19; Critical Illness; Esters; Guanidines; Humans; Mesylates; SARS-CoV-2 | 2021 |